Table 2. Functional program and IDO... | American Society of Hematology

Table 2.

Functional program and IDO competence of murine CD8^- and CD8⁺ DCs subjected to different types of treatment

Type of treatment	In vivo outcome	IDO competence	References
CD8^– DC subset
None	Immunity	–	Grohmann and colleagues,^9,10 Orabona et al²²
IFN-γ	Immunity	–	Grohmann et al,¹² Fallarino et al¹³
IL-6	Immunity^*	–	Orabona et al²²
CTL0-4–Ig	Tolerance	+	Grohmann et al,⁹ Fallarino et al,¹⁵ Orabona et al²²
CD28-Ig	Immunity^*	–	Orabona et al¹¹
CD8⁺ DC subset
None	Tolerance	–	Grohmann and colleagues,^9,10 Orabona et al²²
IFN-γ	Tolerance†	+	Grohmann and colleagues,^10,12 Fallarino et al¹³
IL-6	Immunity	–	Grohmann et al,¹⁰ Orabona and colleagues^22,27
CTL0-4–Ig	Tolerance†	+	Orabona et al²²
CD28-Ig	Immunity	–	Orabonoa and colleagues^11,22

Type of treatment	In vivo outcome	IDO competence	References
CD8^– DC subset
None	Immunity	–	Grohmann and colleagues,^9,10 Orabona et al²²
IFN-γ	Immunity	–	Grohmann et al,¹² Fallarino et al¹³
IL-6	Immunity^*	–	Orabona et al²²
CTL0-4–Ig	Tolerance	+	Grohmann et al,⁹ Fallarino et al,¹⁵ Orabona et al²²
CD28-Ig	Immunity^*	–	Orabona et al¹¹
CD8⁺ DC subset
None	Tolerance	–	Grohmann and colleagues,^9,10 Orabona et al²²
IFN-γ	Tolerance†	+	Grohmann and colleagues,^10,12 Fallarino et al¹³
IL-6	Immunity	–	Grohmann et al,¹⁰ Orabona and colleagues^22,27
CTL0-4–Ig	Tolerance†	+	Orabona et al²²
CD28-Ig	Immunity	–	Orabonoa and colleagues^11,22

Data were compiled from several publications (indicated).

– indicates negative; +, positive.

IL-6 and CD28-Ig reinforce the immunogenic potential of CD8^– DCs, thus allowing these cells to overcome the immunosuppressive properties of untreated CD8⁺ DCs

†

IFN-γ and CTL0-4–Ig reinforce the tolerogenic potential of CD8⁺ DCs, thus allowing these cells to overcome the enhanced stimulatory capacity of CD8^– DCs treated with IL-6

View Large

This Feature Is Available To Subscribers Only